The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or reversible obstructive airway disease. “Metered dose inhalers like these are known as complex generics, which are traditionally harder to copy because of their complex formulation or mode of delivery,” said FDA Commissioner Stephen Hahn, M.D. “As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval. Supporting development and approval of generic copies of these complex medicines so that these products can get to patients has been a major focus of our efforts to improve competition and access and to lower drug prices.”

Related News Articles

Headline
The Medicaid and CHIP Payment and Access Commission published a pair of reports last week. In its March report to Congress, MACPAC, a key congressional advisor…
Headline
The Centers for Medicare & Medicaid Services says it has granted Section 1135 Medicaid waivers to an additional seven states. Nationwide, 23 states have…
Headline
The Centers for Medicare & Medicaid Services on Sunday released a series of COVID-19 checklists and tools for states to use for their Medicaid and Children…
Headline
CMS yesterday updated its FAQ for state Medicaid and Children’s Health Insurance Program agencies, answering questions related to…
Headline
The House Energy and Commerce Health Subcommittee today approved 13 health care bills, including legislation that would reauthorize the AHA-supported Healthy…
Headline
Sens. Jon Tester, D-Mont., and John Hoeven, R-N.D., yesterday introduced AHA-supported legislation (S. 3399) that would renew for five years a…